© Reuters
BOSTON, ROLLE, Switzerland, and MADRID – SOPHiA GENETICS (NASDAQ: SOPH), in collaboration with AstraZeneca (NASDAQ:) Spain, announced today an expansion of their program to enhance access to homologous recombination deficiency (HRD) testing for ovarian cancer across Spain. This initiative aims to support molecular diagnosis and accelerate precision treatment planning for patients.
The partnership, which began in 2022, initially enabled five Spanish laboratories to implement HRD testing, leading to the analysis of over 4,000 samples. With this expansion, SOPHiA GENETICS becomes the preferred partner for HRD testing deployment in Spain, potentially increasing the number of labs with in-house HRD detection capabilities.
HRD is a key biomarker in ovarian cancer, affecting approximately 50% of new diagnoses. It indicates a tumor’s response to certain treatments, making its detection crucial for effective patient care. The collaboration seeks to leverage the SOPHiA DDM™ Platform to improve diagnostics and data-driven treatment strategies.
AstraZeneca Spain, part of AstraZeneca (LSE/STO/NASDAQ: AZN), a biopharmaceutical company, is committed to chronicling cancer and advancing personalized medicine. Marta Moreno, director of Corporate Affairs and Market Access of AstraZeneca Spain, emphasized the importance of biomarker studies in providing personalized treatments with a higher guarantee of effectiveness.
Kevin Puylaert, Managing Director, EMEA, SOPHiA GENETICS, highlighted the significance of local testing for HRD in Spain, which contributes to global data on HRD and advances treatment options for ovarian cancer.
The expansion of this testing program is based on a press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
